Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens

Abstract

An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen. nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid or vaccines comprising the aforementioned to a lymphatic site.

1 - 19 . (canceled) 
     
     
         20 . An isolated nucleic acid encoding SEQ ID NO.: 110. 
     
     
         21 . The isolated nucleic acid sequence of  claim 20  that is SEQ ID NO.: 111. 
     
     
         22 . An expression vector comprising the nucleic acid of  claim 20 . 
     
     
         23 . An expression vector comprising the nucleic acid of  claim 21 . 
     
     
         24 . The expression vector of  claim 22  wherein the vector is a bacterial or a viral vector. 
     
     
         25 . The expression vector of  claim 24  wherein the viral vector is selected from the group consisting of adenovirus, alphavirus, lenti virus, and poxvirus. 
     
     
         26 . The expression vector of  claim 25  wherein poxvirus is selected from the group consisting of vaccinia, fowlpox, avipox, orthopox, canary pox, swinepox, TROVAC, NYV AC, ALVAC(1), ALVAC(2), MVA, Wyeth and Poxvac-TC. 
     
     
         27 . The expression vector of  claim 25  wherein the poxvirus selected from the group consisting of NY VAC, ALVAC, and ALVAC:(2). 
     
     
         28 . The expression vector of  claim 23  wherein the vector is a bacterial or a viral vector. 
     
     
         29 . The expression vector of  claim 28  wherein the viral vector is selected from the group consisting of adenovirus, alphavirus, lentivirus, and poxvirus. 
     
     
         30 . The expression vector of  claim 29  wherein poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC. ALVAC(2), fowlpox, and TROVAC. 
     
     
         31 . The expression vector of  claim 30  wherein the poxvirus selected from the group consisting of NY VAC, ALVAC, and ALVAC(2). 
     
     
         32 . A composition comprising the isolated nucleic acid of  claim 20  and a pharmaceutically acceptable vehicle. 
     
     
         33 . A composition comprising the isolated nucleic acid of  claim 21  and a pharmaceutically acceptable vehicle. 
     
     
         34 . A composition comprising an expression vector of  claim 22  and a pharmaceutically acceptable carrier. 
     
     
         35 . A composition comprising an expression vector of  claim 23  and a pharmaceutically acceptable carrier. 
     
     
         36 . A composition comprising an expression vector of  claim 24  and a pharmaceutically acceptable carrier. 
     
     
         37 . A composition comprising an expression vector of  claim 25  and a pharmaceutically acceptable carrier. 
     
     
         38 . A composition comprising an expression vector of  claim 26  and a pharmaceutically acceptable carrier. 
     
     
         39 . A composition comprising an expression vector of  claim 27  and a pharmaceutically acceptable carrier. 
     
     
         40 . A composition comprising an expression vector of  claim 28  and a pharmaceutically acceptable carrier. 
     
     
         41 . A composition comprising an expression vector of  claim 29  and a pharmaceutically acceptable carrier. 
     
     
         42 . A composition comprising; an expression vector of  claim 30  and a pharmaceutically acceptable carrier. 
     
     
         43 . A composition comprising an expression vector of  claim 31  and a pharmaceutically acceptable carrier,